• Antisense oligonucleotides (ASOs) are increasingly being developed for many indications and are often modified with phosphorothioate linkages in lieu of phosphodiester linkages. • Few in vitro DDI studies with ASOs have been performed, including the investigational imetelstat, volanesorsen, and ISIS 681257.
• The data suggest that phosphorothioate-based oligonucleotide inhibition of P450 and UGT enzymes in HLMs is an in vitro effect without clinical relevance, and that CHHs provide a more clinically relevant inhibitory profile for use in in vitro to in vivo extrapolation (IVIVE) of DDIs. • In vitro P450 inhibition studies with therapeutic phosphorothioate-based ASOs, and the thio-phosphoramidate, Imetelstat, and CHH has shown a lack of in vitro inhibition and consequently no predicted in vivo DDI (Shemesh et al., 2017; Kazmi et al., 2018) , consistent with the results of this study.
• There is a lack of clinical interaction reports for ASOs in the literature, which would reconcile with the lack of in vitro CHH findings by ASOs in this study. . IC 50 plots of CYP1A2, CYP2C8, and UGT1A1 inhibition by phosphodiester-or phosphorothioate-linked oligonucleotides in HLMs. The inhibition of CYP1A2 (phenacetin), CYP2C8 (amodiaquine), and UGT1A1 (estradiol) activity was assessed at 0.1-100 µM oligonucleotide in HLMs at 0.1 mg/ml, with or without a preincubation in the absence of NADPH cofactor (30 minutes) for the evaluation of direct inhibition and TDI, respectively, or in the presence of NADPH cofactor for the evaluation of MDI. Figure 3 . Assessment of the reversibility of CYP2C8 TDI by phosphorothioate-linked oligonucleotides in HLMs. Phosphorothioate oligonucleotides were incubated at 10 µM for 30 minutes in HLMs (0.0125 mg/ml), followed by ultracentrifugation (100,000g) and reisolation of the microsomal fraction. Residual CYP2C8 (amodiaquine) activity was assessed after protein normalization. Publicly available data with oligonucleotide therapeutics, such as eteplirsen, mipomersen, nusinersen, volenesorsen, and defibrotide, have shown no significant pharmacokinetic drug-drug interactions (DDIs) with co-administered medicines (University of Washington DDI database), suggesting that, as a class, ASOs do not affect the metabolic pathways of clearance of small molecule drugs. Upon performing pilot in vitro studies with proprietary phosphorothioate ASO molecules, we unexpectedly observed P450 inhibition in human liver microsomes (HLM). We hypothesized that this was not oligonucleotide sequence specific inhibition, but rather an artifact due to the presence of the phosphorothioate linkage. This observation prompted us to perform the present study with two generic nontherapeutic oligonucleotide sequences (partial sequences to glutathione peroxidase and beta-actin) with and without phosphorothioate linkages as surrogates for therapeutic ASOs. In the present study, phosphorothioate-and phosphodiester-linked oligonucleotides were evaluated as P450 and UGT inhibitors in both HLM and CHH. Furthermore, the potential for select transporter inhibition was also evaluated, specifically the uptake transporters such as organic anion transporting polypeptides (OATP), organic anion transporters (OAT), organic cation transporters (OCT) and the efflux transporters P glycoprotein (P-gp) and breast cancer resistance protein (BCRP). Overall this study reconciles in vitro DDI findings with the lack of interaction in clinical DDI reports for the oligonucleotide biomolecule class.
Note that this poster is based on the following publication which has complete details of the materials and methods: Kazmi A summary of the methods follows: Oligonucleotides. Two ~20 base oligonucleotides with partial sequences towards glutathione peroxidase (5′ GCTCGTTCATCTGGGTGTAGT-3′) and beta actin (5′-CCTCCTCTTTGTTCCCTTCT-3′), each with either a phosphodiester or phosphorothioate linkage (generic structures shown in Figure 1 ) were purchased from Integrated DNA Technologies (Coralville, IA). Test systems. Pooled human liver microsomes (HLM, n = 200, mixed gender) and pooled cryopreserved human hepatocytes (CHH, n = 100, mixed gender) were prepared from non-transplantable livers and characterized at Sekisui XenoTech, LLC (Kansas City, KS). HEK293 cells expressing OATP1B1, OATP1B3, OAT1, OAT3 and OCT2 and control cells were obtained from the ADME & Tox. Research Institute, Sekisui Medical Co., Ltd. (Tokai, Japan); MDCKII cells transfected with BCRP were obtained from Netherlands Cancer Institute (Amsterdam, Netherlands); and Caco-2 cells were obtained from ATCC (Manassas, VA). P450 and UGT inhibition. The effects of oligonucleotides on P450 enzymes in HLM were evaluated (n=2) in IC50 experiments with and without a 30 min preincubation step (in the presence and absence of NADPH) as described previously. For CHH, incubations were conducted in duplicate 100 μL mixtures containing 0.5 million cells/mL in Krebs-Henseleit buffer (KHB). Reactions were initiated by the addition of CHH to the oligonucleotides and incubations were conducted at 37°C with 95% humidity and 5/95% CO2/air for 0, 30 and 90 min, followed by addition of a P450 marker substrate (or the broad specificity UGT substrate 4-methylumbelliferone; 4-MU) at a concentration approximately equal to its Km. For UGT inhibition, assays were conducted as described previously. Briefly, oligonucleotides were incubated in duplicate at 37°C in 150 μL incubation mixtures containing pooled HLMs (≤ 0.1 mg/mL), Tris buffer (100 mM, pH 7.7), MgCl2 (10 mM), EDTA (1 mM, pH 7.4), saccharic acid 1,4-lactone (0.1 mM), UDP-GlcUA (10 mM), and a UGT marker substrate at a concentration approximately equal to its Km as described previously.
Materials & Methods (continued)
In vitro uptake and efflux transporter inhibition. To evaluate inhibition of uptake transporters, HEK293 cells expressing various human uptake transporters were plated in 24-well plates and grown in an incubator (37°C, 95% relative humidity, 5% CO 2 ) for two days. On the day of the assay, cells were pre-incubated with oligonucleotides or solvent control (n=2) for 15 min followed by a 2-min incubation with a combination of probe substrate (a mixture of cold and radiolabeled compound) and oligonucleotide. 50 nM estradiol 17-β-glucuronide substrate was used for OATP1B1 and OATP1B3 assays (with approximate equimolar radiolabeled and cold substrate); 1 μM p-aminohippuric acid for OAT1 (1:4 ratio of radiolabeled to cold substrate); 50 nM estrone 3-sulfate for OAT3 (approximately equimolar radiolabeled and cold substrate); and 5 μM tetraethylammonium bromide and 10 μM metformin for OCT1 and OCT2 respectively (all radiolabeled). Uptake assays were terminated by aspiration of the incubation media followed by washing the cells three times, first a rinse with ice cold PBS containing 0.2% BSA then two rinses with ice cold PBS. For analysis, cells were extracted with 0.1N NaOH for scintillation counting on a Microbeta2 instrument (Perkin Elmer, Waltham, MA). Evaluation of efflux transporter inhibition was conducted in Caco-2 (MDR1/P-gp) or MDCK-II cells (transfected with BCRP) plated on 24-well trans-well plates. The bidirectional permeability of specific probe
